The influence of psychedelics on sexual functioning.
FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit